ArticleCell biology and toxicology2026
EZH2/DUSP1/Akt signaling axis mediates the inhibitory effect of crebanine on hepatocellular carcinoma progression.
Article in Cell biology and toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is characterized by a subtle onset, rapid development, and high malignancy. Traditional treatments have struggled to cure patients with advanced HCC. Crebanine is an isoquinoline aporphine alkaloid extracted from Stephania venosa. Few studies have focused on the therapeutic potential and molecular mechanisms of crebanine in HCC. Herein, to comprehensively evaluate the anti-HCC effect of crebanine in HCC and to further investigate the underlying mechanisms, potential therapeutic role of crebanine against HCC malignancy was assessed through in vitro and in vivo experiments. We carried out a panel of experiments covering cell viability, colony formation, apoptosis detection, migration, invasion and western blot analysis. Results revealed that crebanine suppresses proliferation, migration and invasion, and triggers apoptosis in HepG2 and Huh7 cells. Mechanistically, crebanine treatment increased DUSP1 expression while decreasing EZH2 and p-Akt expressions. Crebanine promoted DUSP1 transcription through repressing EZH2 expression, thereby inhibiting Akt phosphorylation. Knockdown of DUSP1 diminished the anti-HCC effects of crebanine while activating Akt signaling. Overexpression of EZH2 abolished crebanine-induced DUSP1 upregulation and the cytostatic effects in HCC both in vitro and vivo. Overall, crebanine effectively suppresses HCC tumor growth and progression via modulation of the EZH2/DUSP1/Akt signaling pathway. Crebanine shows potential as a promising therapeutic agent for HCC treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.